glp 1 meds and breastfeeding Navigating GLP-1 Pregnancy: Insights, Safety, and Postpartum Considerations GLP1-RAs: The New Era of

Same-day appointments may vary by provider schedule, patient eligibility, and treatment availability

Only half of cancer medicines approved by the European Medicines Agency in 20202023 are available in EU countries (on average) Average time from EMA approval to patient access: 586 days, with major variation between Member States Access to biomarker testing, essential for personalised cancer treatment, is inconsistent across Europe Reducing disparities in access to medicines and diagnostics is essential to ensure innovation benefits all patients, wherever they live

Credit: Carsten Snejbjerg/Bloomberg via Getty Images) Last on More episodes Broadcasts Thu 23 Oct 2025 07:50GMTBBC World Service Thu 23 Oct 2025 11:50GMTBBC World Service Thu 23 Oct 2025 17:50GMTBBC World Service except East and Southern Africa, News Internet & West and Central Africa Thu 23 Oct 2025 21:50GMTBBC World Service East and Southern Africa & West and Central Africa only Fri 24 Oct 2025 02:50GMTBBC World Service except East and Southern Africa, East Asia, South Asia & West and Central Africa Featured in

The underlying mechanism generally consists of the oxidation of redox-reacting cysteine and/or tyrosine residues located within or near the active site, which creates intraprotein and interprotein bridges that affect protein function 8,9